2020 MSU and #MyositisLIFE Sponsors

Learn more about our sponsors

Empowering Myositis Sponsors

MSU is sponsored by Corbus Pharmaceuticals
Corbus Pharmaceuticals

Study researchers are actively recruiting participants for a global, 12-month Phase 3 study testing lenabasum for dermatomyositis. If you are interested in participating or learning more, visit: https://www.corbuspharma.com/clinical-trials/phase-3-study-in-dermatomyositis. The study is organized by Corbus Pharmaceuticals, a company focused on the development and commercialization of novel therapeutics for inflammatory and fibrotic diseases by harnessing its platform of endocannabinoid system-targeting drug candidates. The company’s lead product candidate, lenabasum, is an oral, selective cannabinoid receptor type 2 agonist designed to reverse chronic inflammation and halt fibrotic processes.

Clinical Trial for DMVisit Corbus
Kezar Life Sciences, a 2020 sponsor of MSU and Myositis LIFE
Kezar Life Sciences

Founded in 2015 and based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Kezar believes that the immunoproteasome is a validated target for the treatment of a wide variety of autoimmune diseases given the compelling published activity seen with non-selective proteasome inhibitors administered to patients with severe autoimmune diseases. Kezar is currently recruiting patients to participate in Phase 2 clinical trials. The diseases being studied in these trials are: lupus nephritis, dermatomyositis, polymyositis, autoimmune hemolytic anemia, and immune thrombocytopenia.

Visit Kezar

Understanding Myositis Sponsors

CSI Pharmacy is a sponsor of MSU
CSI Pharmacy

CSI Pharmacy is a nationwide specialty pharmacy, founded by pharmacists, dedicated to servicing patients with chronic and rare illnesses requiring complex care. We are invested in improving the health—and the lives—of the people we serve by offering expert clinicians, passionate advocates, committed healthcare partners and strategic reimbursement experts. Our goal is to optimize patient outcomes, while treating patients as if they were members of our family. Twenty percent of the patients we treat have a form of myositis. We are proud to be a sponsor of Myositis Awareness Month!

Visit CSI Pharmacy
MSU is sponsored by Orphazyme A/S
Orphazyme A/S

Orphazyme is a late-stage biopharmaceutical company focused on developing novel treatment options for patients with rare, orphan diseases. Our work is focused on the cell-protective properties of the heat-shock response, a natural defense mechanism in all our cells. Orphazyme’s lead compound, arimoclomol, is being developed as a potential treatment for several protein-misfolding diseases, including sporadic inclusion body myositis (sIBM). A phase 2/3 clinical trial investigating the use of arimoclomol for sIBM is ongoing with results expected in the first half of 2021.

Clinical Trial for IBMVisit Orphazyme
UCB / Ra Pharmaceuticals

At UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Patient value is not just what we say, but how we live. It is our culture of care, embodied by our patient value strategy. That’s because how we do business – from discovery to development to delivery – has been transformed and redesigned around the patient and their individual experience. Patients are at the heart of everything we do, inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. By fulfilling our commitment, driving innovation, and providing patients a meaningful experience, more impactful solutions are on the horizon.

With a team of approximately 7,500 employees and operations in nearly 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. UCB sites include global clinical development in Raleigh, North Carolina, research supporting UCB’s pipeline in Boston, Massachusetts (Bedford, and Cambridge including our acquisition of Ra Pharma), Seattle, Washington, and Durham, North Carolina as part of our acquisition of Element Genomics, as well as an office in Washington, D.C.

Clinical Trial for IMNMVisit Ra Pharma
MSU is sponsored in part by Diplomat
Diplomat Specialty Infusion Group

Diplomat Speciality Infusion Group is a nationwide specialty pharmacy and infusion group.

Visit Diplomat

Sponsorship opportunities are available

MSU is instrumental in improving the lives of people living with myositis (idiopathic inflammatory myopathies), a group of rare, complicated autoimmune muscle, skin, and often multi-organ diseases, through education, support, awareness, advocacy, access to research, and need-based financial assistance.

We are a fast-growing patient-led 501(c)(3) nonprofit organization with the experience needed to support and advocate for myositis patients and caregivers. Myositis affects the whole person and every aspect of their life. Understanding this disease isn’t limited to symptoms, we push for the inclusion of the patient voice in research and clinical care, and we work to empower the community to acknowledge patients and caregivers as equals – a part of a team – in their healthcare management.

We provide more than support. We continually work hard as an all-volunteer organization providing patient-centered programs and services and building unique and meaningful partnerships in the rare disease community. Technology is a driving force in our continued growth and success; educating, supporting, and connecting patients, caregivers, and family members with one another, and with doctors, researchers, clinical trials, partners, and patient-first focused providers.

Sponsorships include both our comprehensive myositis website, Understandingmyositis.org, and our #MyositisLIFE program and website; giving a voice to patients and caregivers.

#MyositisLIFE is our newest program with a dedicated interactive community-based website, and it provides a solution to a missing piece in awareness and research; the patient voice. 

Contact us for information

© 2020 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy. MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.

The best way to prevent catching or spreading coronavirus is thorough hand washing, social distancing, and social isolation. Should you begin experiencing symptoms of coronavirus, which include fever, cough, and shortness of breath, please contact your doctor immediately. View COVID-19 resources and updates, and stay tuned to your state, local, and federal health agencies, along with the CDC.

Log in with your credentials

or    

Forgot your details?

Register

Send this to a friend